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1. Introduction 
Mood disorders such as depression are the most prevalent diseases amongst psychiatric 
disorders and a leading cause for disability worldwide. Modelling mood disorders in 
animals is a major challenge considering the complex nature of the diseases. Nevertheless, 
existing models and paradigms have proven extremely useful not only with respect to the 
identification and improvement of therapeutic substances, but also regarding the validation 
of neurobiological underpinnings.  
In this chapter we introduce some basic concepts with respect to the questions what and 
how animal models are able to contribute to our understanding of mood disorders. The 
chapter centers on the mouse as the key model organism in neuropsychiatric research and 
gives an overview on the most popular behavioural tests and models with a particular focus 
on major depression. This chapter is not meant to be fully exhaustive considering the 
comprehensive literature on this topic, but rather intends to point out general concepts and 
controversies in the field, for instance to clarify the differences between animal models, 
behavioural tests and antidepressant screening paradigms. Moreover, the chapter will call 
the attention to some novel strategies and technologies that are envisioned to significantly 
impact the future development and application of animal models of mood disorders. 
Finally, the chapter will introduce latest views on the importance of introducing gene  
environment interactions into animal models of etiologic relevance.  
1.1 Epidemiology of depression 
Depression, officially termed major depressive disorder (MDD) ranks among the most 
prevalent diseases worldwide. According to the estimations of the World Health 
Organization, depression will be the second leading cause of disability in 2020 (Murray and 
Lopez, 1997). Recent epidemiological studies indicate that severe forms of depression affect 
2-5% of the population worldwide, and up to 20% are affected by milder forms of the 
disease (Kessler et al., 2003). Moreover, depressive patients have a 2-4 fold increased risk of 
developing cardiovascular diseases and 10-15% of individuals with major depression 
commit suicide (Keck, 2006). 
Up to now, depression is diagnosed according to criteria in the Diagnostic Manual of Mental 
Disorders (DSM-IV), which characterizes a major depressive episode by at least five of the 
following symptoms: (1) depressed or irritable mood, (2) decreased interest or loss of 
pleasure, (3) weight gain or loss, (4) insomnia or hypersomnia, (5) psychomotor retardation 
or agitation, (6) fatigue or loss of energy, (7) feelings of worthlessness or inappropriate guilt, 
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(8) diminished ability to think or concentrate, (9) recurrent thoughts of death and suicide. 
The symptoms must be evident almost daily for at least 2 weeks. Additionally, symptoms of 
anxiety are also often seen in depressed individuals (Berton and Nestler, 2006). 
The genetic risk to develop depression is 40–50% (Levinson, 2006), but there are also several 
environmental risk factors for MDD. These include gender, stressful life events, adverse 
childhood experiences and certain personality traits (Fava and Kendler, 2000). Many recent 
studies support the hypothesis that stressful events correlate with an increased vulnerability 
for depression in a way that stressful situations often precede the onset of illness and are 
also associated with the severity of depression (Brown et al., 1987;Dunner et al., 
1979;Holsboer, 2001;Nemeroff, 1988).  Such stressors can lead to a transient hyperactivation 
of the hypothalamic-pituitary-adrenocortical (HPA) axis, resulting in increased 
glucocorticoid secretion. In this regard, depression is often associated with a dysregulation 
of the HPA axis under chronic stress conditions (Holsboer and Barden, 1996). Additionally, 
treatment of depressed patients with antidepressants can restore the homeostasis of the 
HPA axis and thereby contributes to clinical improvement (Holsboer, 2000;Holsboer and 
Barden, 1996). 
In contrast to the epidemiological magnitude of the disease, the progress of pharmacological 
therapy for depression is still limited (Nestler et al., 2002). All available antidepressants act 
via monoamine neurotransmitter systems, but only 50-70% of the patients exhibit acceptable 
responses to treatment (Morilak and Frazer, 2004). Additionally, slow onset of clinical effects 
as well as severe side effects associated with antidepressant therapy frequently lead to 
discontinuation of treatment. Although the latest generation of drugs has fewer side effects, 
they still exhibit similar effectiveness rates and show a substantial delay of 4-6 weeks 
between onset of treatment and clinical improvement. Beside that, 25-35% of the patients 
remain resistant to the treatment even after 6 weeks of therapy (Berton and Nestler, 
2006;Holsboer, 2005). Apart from monoamines, many other targets have been analyzed, 
including glucocorticoid receptor and corticotropin-releasing hormone receptor antagonists 
(Berton and Nestler, 2006;Grigoriadis, 2005) as well as histone deacetylase inhibitors 
(Covington, et al., 2009). However, so far none of these studies has resulted in a new 
adequate treatment of the disease. Besides these aspects, the molecular mechanisms 
underlying depression still remain largely unknown.  
All these arguments raise the necessity of finding novel approaches to discover different 
targets for antidepressant treatment and of developing new mouse models to study the 
effects of monoamine and non-monoamine-related molecules. 
1.2 The endophenotype concept – modelling symptoms of depression in mice 
1.2.1 The endophenotype concept 
The highly variable composition of symptoms, course of illness and response to treatment 
renders it very difficult to accurately define and consequently diagnose depression. The so-
called psychopathological endophenotypes represent key symptoms of major depression. 
An endophenotype represents a trait that is intermediate between genotype and disease, not 
necessarily beholden to the diagnostic criteria for single illness, but in many cases useful to 
simplify our understanding of complex or heterogeneous disorders (Shyn and Hamilton, 
2010). An endophenotype is associated with illness in the population, is heritable and is 
primarily state-independent. Furthermore, endophenotype and illness co-segregate within 
families and the endophenotype found in affected family members is found in nonaffected 
family members at a higher rate than in the general population (Gottesman and Gould, 
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2003;Gould and Gottesman, 2006). The methods available to identify endophenotypes 
include neuropsychological, cognitive, neurophysiological, neuroanatomical, and 
biochemical measures (Hasler et al., 2004). 
1.2.2 Depression-associated endophenotypes in mice 
Mimicking any human behavioural trait in a mouse is extremely difficult, which makes the 
undertaking to try and model a multifactorial disease such as depression nearly impossible. 
How do we recapitulate all aspects of depression in an animal, when the criteria used to 
classify a major depression are of extreme heterogeneous and sometimes even of opposite 
nature (e.g., substantial weight gain or loss, insomnia or hypersomnia)? On top of that, 
animals not only lack consciousness of self, self-reflection and consideration of others but 
also aspects of the disorder such as depressed mood, low self-esteem or suicidality 
(Deussing JM, 2006). This does not mean that it is impossible to develop useful animal 
models, but rather highlights the unlikelihood of generating a model that will mirror the full 
extent of a given human neuropsychiatric disorder (Nestler and Hyman, 2010). Nonetheless, 
in depression, as well as other mood disorders, certain endophenotypes can be reproduced 
independently and evaluated in animals (Table 1). As mentioned above, these include 
physiological, endocrinological, neuroanatomical and behavioural alterations, many of 
which can be measured in mice.  
So far a variety of different mouse models have been established to improve our 
understanding of the pathophysiology of a wide spectrum of psychiatric diseases. However, 
a full consensus regarding the prerequisites of a valid animal model is still lacking in the 
scientific community. Up to now, the three criteria set up by McKinney and Bunney 
(McKinney and Bunney, 1969) are still widely accepted; they include construct validity, face 
validity, and predictive validity.  
Construct (or etiologic) validity, the most complex of the three terms, requires that the 
symptoms produced in the animal model are based on the same underlying neurobiological 
mechanisms as in humans. Thus, one tries to recreate mechanisms/processes in the animal 
which would also initiate the disease in humans (Nestler and Hyman, 2010). The ideal way 
would be to introduce a known human disease-causing gene variant into a mouse and 
thereby alter intracellular mechanisms, which in the end lead to the disease (Chadman et al., 
2009). Unfortunately this is currently far from being realistic, since most disease-causing 
genetic alterations have not been established with certainty and the probability that a single 
gene is solely responsible for the disease is highly unlikely. In addition, an animal model 
does not have to be based on a genetic change, but can also be subject to an environmental 
challenge or a combination of both.  
Face validity is achieved when the animal exhibits specific symptoms of the disease which 
are similar in the human condition. These can be of biochemical, anatomical, 
neuropathological or behavioural nature. Thus the concept of face validity can also be 
regarded as the attempt to reproduce certain endophenotypes which can be accurately 
measured in the animal.   
Finally, predictive validity refers to the ability of the animal to correctly respond to 
pharmacological treatment, which should correlate with results from clinical trials.  
In this context, it is important to note that the more criteria the proposed model meets, the 
more compelling it will be (Malkesman et al., 2010). Simply put, researchers are faced with the 
challenge of 1) constructing a model with similarity in disease progression and 
symptomatology to humans, 2) detecting these phenotypes with the appropriate behavioural 
tests and 3) reverting them with treatment modalities that are also effective in humans. 
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DSM-IV symptoms Endopenotypes in mice Appropriate test/analysis
Depressed or irritable mood Cannot be modeled
Decreased interest or loss 
of pleasure
Anhedonia
Sucrose preference              
Intracranial self-stimulation          
Conditioned place-preferance      
Female urine sniffing
Weight gain or loss Can easily be measured
Abnormal loss or gain of weight 
after stress
Insomnia or hypersomnia Abnormal sleep architecture
Assessed by 
electroencephalogram          
recordings
Psychomotor retardation or 
agitation
Alterations in  locomotion
open field                        
alterations of homecage activity   
treadmill running                        
Gate analysis
Fatigue or loss of energy Alterations in  locomotion
Reduced homecage activity 
Treadmill running                      
Nest building
Feelings of worthlessness 
or inappropriate guilt
Cannot be modeled
Diminished ability to think or 
concentrate
Deficits in working and spatial 
memory
Morris water maze                     
Y-maze                                     
fear conditioning              
Attentional set-shifting





Open field                          
Elevated plus maze                
Dark-light box                         
Novelty-induced hypophagia 
Novel object exploration   
Modified hole board            
Marble burying
Changes in social behavior
Social interaction/avoidance        
Sociability
Behavioral despair
Forced swim test                       
Tail suspension test                 
Learned helplessness
Neuroendocrine disturbances
Alterations in corticosterone 





Analysis of hippocampal volume 
by resonance imaging                
(often reduced in depressed 
patients)  
Table 1. Depression-associated endophenotypes that can be modelled in mice. 
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Although progress has been made to identify the underlying molecular mechanism of 
depression, the lack of specific markers and biomarkers still represents a major drawback. In 
contrast to many other illnesses such as cancer, infectious diseases, cardiovascular arrest, 
diabetes, stroke, etc., depression cannot simply be diagnosed by making use of the usual 
methods, such as assessing blood pressure, glucose levels, inflammatory agents, heart rate 
and others. Clinicians still fully rely on observations and verbal communication. Therefore, 
behavioural tests that are used to assess phenotypic alterations relevant to depression in 
mice are of extreme importance and will be discussed in more detail. 
2. Behavioural tests – tools used to assess phenotypic alterations in animal 
models 
First, we want to point out the importance of discriminating between an animal model, a 
behavioural test and an antidepressant screening paradigm. Animal models, as discussed 
above, are expected to show sufficient construct, face and predictive validity. Behavioural 
tests on the other hand are used to assess phenotypic alterations relevant to the disease and 
should be regarded as a technical tool and not a model (Table 1). Likewise, antidepressant 
screening paradigms, such as the forced swim test, also do not represent a model of 
depression but should rather be regarded as drug-screening assays.  
Nowadays researchers are discordant when it comes to the term “depression-related test”. 
Given the fact that there is no consensus as to what can be regarded as “depression-like” 
behaviour in animals it has become increasingly popular to look at, and talk of behavioural 
endophenotypes or sub-categories, which in some cases may, and in others may not 
represent aspects of depression. These include anxiety-, reward-, social and despair-based 
behaviour as well as alterations in general locomotion, sleep, food and liquid intake.  
2.1 Tests assessing despair-based / stress-coping behaviour 
In earlier days, the Porsolt forced swim test (FST) and the tail suspension test (TST) were 
regarded as typical depression-like paradigms, given the fact that both were developed to 
screen monoamine-based antidepressant drugs. This is currently a matter of debate, since both 
assess the response to an acute inescapable stressor, provoking despair-based 
behaviour/immobility or stress-coping behaviour rather than depression-like behaviour. The 
FST makes use of the fact that rodents eventually develop immobility when being placed in a 
cylinder of water after they have stopped active escape behaviours, such as climbing or 
swimming (Cryan and Holmes, 2005) A related task is the TST, which relies on similar 
assumptions and interpretations as the FST. Here the mice are hung upside down by their tails 
and the time spent immobile is assessed. One major advantage of the TST is that it is not 
confounded by stressful hypothermia as is the case in the FST. However, the TST is restricted 
to strains that do not tend to climb their tail which otherwise confuses the interpretation of 
behavioural measures (Mayorga and Lucki, 2001). In either case the underlying principles 
measuring the lack of active coping behaviour are identical. However, the question whether 
immobility should be interpreted as passive stress-coping, behavioural despair or even 
depression-like behaviour remains controversial. One aspect favouring the stress-coping 
rather than depression-like aspect of the FST are the outcomes when manipulating the 
corticotropin-releasing hormone (CRH) system. CRH overexpressing animals as well as 
central application of CRH result in decreased immobility (Butler et al., 1990;van Gaalen et al., 
2002;Lu et al., 2008). However, it is widely believed that high levels of CRH are rather pro-
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depressive (Holsboer and Ising, 2008) and it was shown that CRHR1 antagonists have an effect 
similar to paroxetine and other antidepressants (Holsboer and Ising, 2008). Thus it is likely that 
the CRH/CRHR1 stress system also accounts for regulating and/or triggering responses to the 
test (Refojo and Deussing, 2011). In that regard, Gardier already pointed out that the FST 
assesses stress-induced anxiety rather than depression (Gardier and Bourin, 2001). In addition, 
it is very unlikely that such a short period of inescapable stress is able to induce a depression-
like state in a wild-type animal. Nevertheless, the FST and TST have proved reliable across 
many laboratories by demonstrating their ability to detect a broad spectrum of substances with 
antidepressant efficacy, all of which reduce immobility. However, most effects are already 
observed after acute treatment, which contrasts the human situation, where chronic 
application of antidepressants is necessary to achieve clinical responses (Nestler and Hyman, 
2010). For this reason, we believe that the FST and TST should rather be viewed as paradigms 
designed to assess strategies of stress-coping behaviour and monoamine-based antidepressant 
action (Lucki, 1997), and not as models of depression (Refojo and Deussing, 2011).  
In addition to the FST and TST, the learned helplessness paradigm also makes use of 
stressor uncontrollability and passive vs. active coping responses (Cryan and Holmes, 2005). 
The paradigm is based on the observation that animals exposed to uncontrolled or 
unpredictable aversive events (e.g. electrical shocks) for a sufficient period of time will 
develop long-lasting deficits in escape performance (Seligman and Maier, 1967). Short-term 
treatment with antidepressants as well as anxiolytics has shown to reverse the enforced 
behavioural phenotype, which doesn’t make the paradigm particularly selective (Cryan and 
Mombereau, 2004). In addition, only some of the animals develop signs of helplessness and 
those are usually short-lived. Similar to the FST and TST, the learned helplessness paradigm 
does not parallel clinical settings with regard to the slow onset of antidepressant action, but 
remains a good tool for the assessment of stress-coping behaviour (Deussing, 2006).  
2.2 Anxiety-based tests 
The lack of clear a distinction between depression and anxiety amongst researchers poses a 
major issue in the interpretation of behavioural tests. Depression, by definition, is 
considered a pathological mental condition. Anxiety, however, is a normal state of cognitive 
and behavioural preparedness that an organism mobilizes in response to a future or distant 
potential threat (Leonardo and Hen, 2008). Although anxiety is often necessary and even 
protective, excessive anxiety can trigger disabling responses that, in time, lead to anxiety 
disorders (e.g., generalized anxiety disorder, social phobia, simple phobia, panic disorder, 
posttraumatic stress disorder (PTSD), and obsessive compulsive disorder) (Bienvenu et al., 
2009). Anxiety can often emerge as part of a depressive syndrome, but this does not hold 
true for all patients and certainly not for all animal models (Krishnan et al., 2007;Wallace et 
al., 2009). It is also important to note that the underlying neural circuitries are believed to be 
different in depression and anxiety (Nestler and Hyman, 2010). However, in animal models 
anxiety is considered a core endophenotype of depression, which is mainly due to the 
availability of a wide range of standardized tests, all of which assess anxiety-like behaviour. 
Most of these assays are based on approach-avoidance conflicts and were developed and 
validated using classical benzodiazepine-like anxiolytic compounds. Mice generally display 
high levels of exploration of a novel environment but also have an innate aversion to enter 
exposed, well-lit areas. The elevated plus-maze (EPM) and elevated zero-maze present the 
subject mouse with the choice of spending time exploring the open areas of a plus-shaped or 
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circular runway, versus spending time exploring the enclosed arms and arcs (Handley and 
Mithani, 1984;Chadman et al., 2009). Other exploration-based tasks, founded on similar 
conflicting tendencies to approach versus avoid a potentially dangerous area are the dark-
light box (DaLi) and open field (OF) test. In the latter the aversive area is represented by the 
central zone of a brightly lit open field. In the dark-light box test averseness is achieved by a 
highly illuminated compartment (Lister, 1990;Belzung and Griebel, 2001). The novel object 
exploration test makes use of similar principles, the only difference being that mice are first 
habituated to an environment and then exposed to novelty (novel object). Explorative 
paradigms such as the EPM, DaLi and brightly lit OF have been suggested to measure state 
anxiety (Belzung and Le, 1994;van Gaalen and Steckler, 2000). In contrast, exploration of 
novelty in an area known to be safe has been suggested to fundamentally differ from the 
exploration of a totally new environment and thus claimed to reflect trait rather than state 
anxiety (Griebel et al., 1993;van Gaalen and Steckler, 2000). Other tests are the modified hole 
board the mirrored chamber test, the staircase test and the marble burying test (Broekkamp 
et al., 1986;Holmes, 2001;Belzung and Griebel, 2001;Ohl et al., 2003). Another emerging 
paradigm is the novelty-induced suppression of feeding test, which measures the latency 
until food consumption in a novel environment. Here, rodents have shown to respond to 
chronic but not acute antidepressant treatment, resulting in decreased latency to feed 
(Dulawa and Hen, 2005). This goes along with the fact that anxiety in humans can in many 
cases be treated with chronic antidepressant administration (Nestler and Hyman, 2010).  
Even though approach-avoidance tests are critical in the assessment of anxiety-related 
behaviour in mice, they still have to be interpreted with caution. In most of the tests it is not 
possible to distinguish between an anxiety response and other phenotypes such as motivation, 
novelty-seeking, impulsivity or arousal. Thus increased time spent in an aversive area can be 
interpreted as both, decreased anxiety or increased motivation or arousal. Different 
exploratory and even coping strategies can also be misinterpreted as alterations in anxiety-like 
behaviour. Additionally, tests based on exploration can be strongly influenced by differences 
in basal locomotion and cognition (Refojo and Deussing, 2011). As is the case with the FST and 
TST, the above mentioned anxiety-based assays represent useful initial screens, but should 
never be used as definite evidence of a depression-like phenotype. This emphasizes the 
importance of parallel use of several slightly different anxiety tests, as well as the utilization of 
internal controls with respect to locomotion. Most importantly, additional non-anxiety based 
tests should be considered (see below).  
2.3 Reward-related and anhedonic behaviour 
Anhedonia, a hallmark of depression is defined as the inability to experience pleasure from 
activities formally found enjoyable. Dopamine neuronal functioning is essential in 
sustaining a wide variety of pleasurable and rewarding experiences (Wise and Bozarth, 
1985;Wise, 2002). Especially dopaminergic neurons, projecting from the ventral tegmental 
area to the prefrontal cortex, basolateral amygdala, and nucleus accumbens are essential in 
reward processes (Wise, 2002). The most widely accepted approach to assess reward-
seeking behaviour is via the sucrose consumption and preference tests. Decreased intake of 
palatable solutions, such as sucrose is regarded as a behavioural measure of hedonic 
deficit/depressive-like state (Willner, 2005). One drawback, however, is that one cannot rule 
out appetitive, metabolic or sensorial influences, which may be altered in genetically 
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modified animals. In addition, enhanced hedonic drive and motivation, which are hallmarks 
of manic symptoms in bipolar disorder, may often be misinterpreted as decreased 
depression-like behaviour (Hasler et al., 2004). Operant paradigms, such as the conditioned 
place-preference (CPP), are also widely applied to assess anhedonic behaviour. Although 
mainly used to determine the addiction potential of drugs, CPP can also be employed to test 
animals in a drug-free state. Even though methodological details differ among laboratories, 
a typical CPP experiment includes differential pairing of two distinct sets of environmental 
(contextual) cues with a stimulus (e.g., drug, food, copulatory opportunity) (Bardo and 
Bevins, 2000). When tested later on in the absence of the stimulus, the approaches and the 
amount of time spent in the compartments previously associated with the positive stimulus 
serve as an indicator of preference and a measure of reward learning. Obvious drawbacks 
include the rather elaborate testing procedure as well as the fact that the paradigm is heavily 
dependent on learning, memory and motor activity. Operant self-administration, using the 
so-called operant box (or Skinner box), represent additional methods in anhedonic research 
(Sanchis-Segura and Spanagel, 2006). In contrast, intracranial self-stimulation-based 
procedures make use of the phenomenon that direct stimulation of distinct brain regions 
through electrical or chemical means can activate the reward system and serve as an operant 
reinforcer (Sanchis-Segura and Spanagel, 2006). However, the use of brain stimulation 
reward techniques requires surgery and sometimes extensive periods of training that often 
exceed the recovery time from the surgery (Malkesman et al., 2010). Alternatives are for 
instance the recently developed female urine sniffing test (FUST). The FUST is a nonoperant 
test, designed to measure reward-seeking behaviour in rodents based on the interest in 
pheromonal odors from the opposite sex (Malkesman et al., 2010). The duration of female 
urine sniffing was significantly decreased after foot-shock stress and could be reverted upon 
antidepressant treatment (Malkesman et al., 2010). As with other tests, the FUST faces 
limitations when working with transgenic animals, which in some cases may suffer from 
olfactory system dysfunction (Hull and Dominguez, 2007). Furthermore, the preference for 
estrus female odour might also be related to social and not just sexual behaviour (Wersinger 
et al., 2004). As with anxiety tests, multiple tasks that evaluate different aspects of reward 
sensitivity should be considered, and are likely to provide more insights into the 
behavioural and neurobiological processes of mood disorders such as depression.  
2.4 Cognition-based tests 
A majority of depressed patients, especially older adults, show pronounced cognitive 
deficits typically consisting of memory impairments, poor attention, and executive 
dysfunction (Butters et al., 2004;Crocco et al., 2010). Hence, it is of great interest to model 
altered cognitive behaviours in mice. However, this undertaking faces many challenges, 
given the fact that the rodent cortex is much more primitive than the human, which 
makes it extremely difficult to address many aspects of cognitive processing in mice 
(Cryan and Holmes, 2005). Therefore, many of the applied cognition tasks, such as the 
Morris water maze (MWM) and Y-maze test, focus on general cognitive function 
mediated by the hippocampal region. Developed by Morris in 1984, the MWM test 
assesses spatial learning in mice and rats and is strongly reflective of hippocampal 
synaptic plasticity and NMDA receptor function. The test relies on distal, visual cues that 
can help the animal to locate and navigate to a submerged escape platform from different 
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starting locations within an open swimming arena. Spatial learning is evaluated across 
repeated trials and reference memory is assessed by preference for the platform area once 
the platform is absent (Morris, 1984;D'Hooge and De Deyn, 2001). Similarly, the Y-maze 
also assesses spatial memory and hippocampal integrity. It is based on the animal’s 
natural curiosity to discover novel environments (Conrad et al., 1996;Dellu et al., 2000), 
but is not confounded by possible effects of hypothermia. Incidents of chronic social 
stress, a precondition of many depressed patients, have shown to alter cognitive 
performance in a battery of tests including the MWM and Y-maze task (McEwen and 
Sapolsky, 1995;Song et al., 2006;Wang et al., 2011).  
It is important to note that many cognitive deficits, such as misappraisal and over-attention 
to threatening stimuli, are also observed in panic disorder, generalized anxiety disorders 
and phobias (Cryan and Holmes, 2005). Thus, researchers often speak of emotional 
cognition, which can be analysed in rodents with certain well established concepts such as 
Pavlovian fear-conditioning (Davis, 1990;Fendt and Fanselow, 1999;Maren, 2001). Such 
contextual and cued fear conditioning tasks represent additional methodologies to 
investigate memory, as they require that the animals learn the association of a non-aversive 
context or cue with an aversive stimulus. The ability to learn this association is measured by 
the amount of freezing exhibited in response to the cue or context alone (Amann et al., 2010). 
Many variations of the paradigm exist, including altering the type of cue and stimulus, and, 
once learned, testing the rate at which learning is extinguished (Fanselow, 1980). The failure 
to extinguish learned fear responses is one key feature of post-traumatic stress disorder, 
phobias and other anxiety disorders (El-Ghundi et al., 2001).  
Another recently validated test in rats is the attentional set-shifting test (Birrell and 
Brown, 2000;Bondi et al., 2008). The animals are trained to dig for food in bowls which are 
presented in pairs, only one being baited. The rat has to select the bowl to dig in based on 
the texture that covers the bowl’s surface or the odor of the medium with which it is 
filled. Once the training procedure is completed, the animals perform a series of 
discrimination tasks, including reversal, an intradimensional shift, and an 
extradimensional shift. The number of trials required to perform six consecutive correct 
responses in different stages is scored. Rats subjected to chronic unpredictable stress 
exhibited impairments in the attentional set-shifting test, which were prevented by 
desipramine or escitalopram treatment (Bondi et al., 2008). In addition, lesions of the 
medial prefrontal cortex selectively disrupted extradimensional set shifting (Birrell and 
Brown, 2000). Although this paradigm is quite labour intensive and not yet validated for 
the mouse, it represents a very interesting means to evaluate prefrontal cortex function as 
a cognitive trait relevant for depression.  
Although cognitive tests are not used as standard tools when assessing depression-like 
behaviour, they certainly provide insights into the cognitive aspects of the emotional state. 
Thus, it is strongly recommended to include cognitive tasks in schedules for testing 
emotional behaviour especially in combination with some of the well-established anxiety 
tests described above.  
2.5 Assessing behaviour via social tests  
Social behaviour can be defined as any behaviour that influences, or is influenced by, other 
members of the same species. A variety of neuropsychiatric disorders, including depression, 
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are characterized by disruptions of social behaviour (Nestler and Hyman, 2010). Many of the 
social test paradigms were originally developed to study schizophrenia and autism-like 
behaviour, in which alterations in social behaviour represent core symptoms of the disease. 
However, social withdrawal also represents a common symptom in psychiatric conditions 
such as depression, social phobia, and PTSD (Berton and Nestler, 2006). Exposure to chronic 
social stress, after which rodents show signs of anhedonia and increased anxiety-like 
behaviour, is also effective in inducing social withdrawal (Krishnan et al., 2007). Although 
most social tasks in mice are employed after repeated exposure to a stressor, it should be 
considered to employ these tests also under basal conditions especially when evaluating 
transgenic mouse lines.  
The classical social interaction paradigm encompasses the free exploration of an unfamiliar 
congener by the experimental mouse. Social interaction is measured by the time spent in 
close proximity to the unfamiliar mouse as well as the amount and duration of additional 
behaviour including sniffing, following, grooming, biting, mounting etc. In many cases, 
social avoidance behaviour is associated with anxiety- and depression-like behaviour.  
The social avoidance paradigm represents a similar but faster and more systematic approach 
to assess social avoidance. In contrast to the standard tests, social approach towards an 
unfamiliar mouse enclosed in a wire mesh cage is measured (Berton et al., 2006). This 
excludes subject bias from the observer, since only the time spent in close proximity to the 
target is assessed. In addition, aggressive behaviours such as biting and fighting can be 
excluded. Other paradigms, including the sociability test can be used to assess the social 
preference between a stranger/conspecific and an object (Moy et al., 2004). In addition, 
social novelty can be evaluated by introducing a second unfamiliar mouse. In rats, it was 
shown that social behaviour is individually stable and that sociability is related to 5-HT 
metabolism in the prefrontal cortex (Tonissaar et al., 2004;Tonissaar et al., 2008b). 
Additionally, sociability and anxiety were shown to be closely related domains (Tonissaar et 
al., 2004;Tonissaar et al., 2008a). Even though preclinical research has clearly favoured the 
rat for the assessment of social behaviour, the propagation of transgenic and gene targeting 
technologies in the mouse has established it as a unique model in psychiatric research. Thus, 
an ever increasing number of social tasks is established in mice and should definitely be 
considered when assessing animal models of depression. 
3. Outline of existing mouse models of depression 
Most animal models of depression are either based on environmental challenges or on 
manipulation of sensory and integrative functions of the brain. By means of a variety of 
stressful conditions, certain symptoms that are inferred to be “depression-like” can be evoked 
in animals. In contrast, molecular and cellular tools, which allow the development of targeted 
genetic manipulation strategies in embryonic stem cells, are also widely applied to generate so 
called “depression models”. Below, the most prominent and widely used animal models of 
depression will be considered. In addition, innovative strategies and state-of-the-art 
technologies used to construct novel genetic mouse models of depression will be discussed.  
3.1 Lesion models 
Patients exhibiting depression or other psychiatric syndromes often show alterations in 
structures related to olfactory function. Olfactory performance was shown to be reduced in 
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depressed patients (Pause et al., 2001) together with morphological differences in olfactory 
projection areas, noticeably in the amygdala (Nestler et al., 2002). Thus, the bulbectomized 
rat or mouse has been considered a model of agitated depression (Leonard and Tuite, 
1981;Kelly et al., 1997). After ablation of the olfactory bulb, mice demonstrate typical loss of 
smell but also disruptions of the limbic-hypothalamic axis with the consequence of 
behavioural, neurochemical, neuroendocrine and neuroimmune alterations, all of which 
may resemble changes in depressed patients (Song and Leonard, 2005). The behavioural 
outcome of olfactory bulbectomy is largely thought to result from compensatory 
mechanisms of neuronal reorganisation. Thus, most of the literature indicates that the 
olfactory bulb is not a mere sensory area, suggesting that it could have non-olfactory 
functions relevant for modulation of behaviour (Edwards et al., 1972;Cain and Paxinos, 
1974;Mucignat-Caretta et al., 2004). In addition, peripheral anosmia fails to produce the 
observed behavioural changes in mice, indicating once more that loss of smell alone is not 
the sole cause for the observed syndromes (Mar et al., 2000). Underlying changes are 
thought to involve alterations in synaptic strength and/or loss of spine density in various 
limbic regions including the amygdala and hippocampus (Kelly and Leonard, 1999). 
Marked changes in major neurotransmitter systems have also been observed in 
bulbectomized rodents (Kelly, 1999). However, the most consistent behavioural phenotype 
of bulbectomized animals is a hyperactive response in the open field paradigm, which is 
reversible upon antidepressant treatment (Cryan et al., 1999). This model of depression 
shows high face validity as it mimics the slow onset of antidepressant action reported in 
clinical studies (Willner and Mitchell, 2002). However, high construct validity is not 
achieved as the model fails to recapitulate the etiology of disease progression.  
3.2 Pharmacological models 
Pharmacological models in the ideal sense should induce behavioural changes and 
treatment responses partly similar to depression. Reserpine, a sympatholytic drug that 
depletes catecholamines in the brain (Eranco and Hopsu, 1958;Mascorro and Yates, 1971), is 
believed to chemically evoke a depression-like phenotype in animals. The drug was shown 
to induce a syndrome of locomotor hypomotility and reduced body temperature in rodents. 
In addition, reserpine exhibits effects on the adrenal glands which resemble those of 
physiological stress (Joh et al., 1973). This model is based on the capability of 
antidepressants to reverse the inhibitory effects caused by reserpine on motility in rats and 
mice (Nutt, 2006). The psychostimulant withdrawal paradigm, another widely applied 
pharmacological model, displays both, responsiveness to antidepressants and induces 
characteristic symptoms of depression. In humans, withdrawal from chronic 
psychostimulants generates symptoms that have strong behavioural and psychological 
parallels to depression including diminished interest in pleasure. Withdrawal from chronic 
amphetamine treatment results in behavioural changes that were shown to be analogous to 
some aspects of depression. These included reward deficits and increased immobility in the 
FST (Kokkinidis et al., 1986;Cryan et al., 2003). Therefore, examination of the behavioural 
effects of drug withdrawal may provide insights into the underlying neurobiological 
mechanisms and aid in the development of animal models of depression that are sensitive to 
antidepressant agents. Although many of these models show robust predictive and even 
face validity, most of them fail to mimic disease etiology. In that regard, pharmacological 
models such as those mentioned above, significantly contributed to the strengthening of the 
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monoamine theory of depression, which assumes that an elevation of serotonin and 
norepinephrine levels will improve depressive symptomatology. However, they are limited 
in their value as effective models of depression given the ever expanding impact of genetic 
and environmental models. 
3.3 Genetic mouse models  
Genetically engineered mice represent a powerful tool to study candidate genes thought 
to participate in a particular disease. In general, scientists discriminate between forward 
and reverse genetics. Forward genetics allows the identification of relevant genes without 
any prior knowledge of genetic or mechanistic underpinnings of a phenotype of interest. 
Classically, forward genetics involves larger scale random mutagenesis screens such as 
ENU-(N-ethyl-N-nitrosourea) or gene-trap-based approaches which have resulted in a 
great number of mutants displaying aspects of depression-like behaviour. On the other 
hand, reverse genetics involves genetic manipulations that result in loss- or gain-of-
function mutants. These include classical transgenic mice that have additional copies of 
certain genes in their genome, which results in a gain-of-function. Similarly, knock-in 
techniques are frequently applied to generate gain-of-function animals. However, 
transgenes can also be used to induce a loss-of-function if the inserted transgene produces 
an antisense mRNA of the target gene. Similarly, short hairpin RNAs directed against the 
gene of interest have also been widely used (Kleinhammer et al., 2010). However, 
disruption of specific target genes is most commonly achieved via generation of knockout 
mice. Embryonic stem (ES) cell technology has been widely used to produce null mutants 
or ‘conventional’ knockouts (Capecchi, 2005). In that case, the targeting vector is 
constructed to allow the precise disruption of a gene resulting in the complete ablation of 
protein and/or mRNA production within every cell. Such conventional knockout mice 
were of immense importance in identifying candidate genes involved in depression and 
other mood disorders (see below). However, they were limited in their ability to further 
uncover specific brain regions and neural circuitries involved in disease etiology. In many 
cases, homozygous knockouts were not viable or induced developmental and peripheral 
changes such as reduced weight or organ dysfunction. Since then, technologies in this 
field have expanded rapidly, introducing sophisticated conditional strategies (Branda and 
Dymecki, 2004). This progress has allowed an increasingly refined control of spatial and 
temporal gene expression. In particular, the propagation of site-specific recombinases 
makes it possible to address gene function in a spatially and temporally restricted 
manner. For example, mouse lines expressing Cre recombinases selectively in neurons of 
a specific neurotransmitter type allow for gene targeting of specific populations of 
neurons. Moreover, increasing availability of mouse lines expressing the tamoxifen-
inducible Cre recombinase variant CreERT2 (Branda and Dymecki, 2004) offers additional 
temporal control and avoids obscurities due to developmental functions of targeted genes. 
In addition, conditional strategies such as RNAi technology or virus-mediated genetic 
manipulation also enable the control over spatial and temporal gene expression, and are 
thus becoming increasingly important. 
Currently, three main theories try to conceptualize the molecular mechanisms underlying 
depression. These include the monoamine and neurotrophic hypothesis, and the HPA 
system. Thus, most genetic approaches aim at altering the expression of genes that are 
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involved in these systems and thereby analyse their respective role in animal behaviour, 
neuroendocrine and molecular parameters (Urani et al., 2005). The monoamine hypothesis 
postulates that depression is caused by an impairment of serotonergic, noradrenergic or 
dopaminergic neurotransmission. The monoaminergic deficiency can be due to several 
factors including decreased synthesis or early degradation of neurotransmitters, altered 
expression or function of neurotransmitter receptors and impairment of signal transduction 
systems activated by post-synaptic neurotransmitter receptors (Berton and Nestler, 2006).  
The neurotrophic hypothesis of depression assumes that the cAMP responsive element-
binding protein (CREB) – brain derived neurotrophic factor (BDNF) – tyrosine kinase B 
receptor (TRKB) pathway is involved in the pathophysiology of depression and action of 
antidepressants. Originally the theory was based on findings in rodents, demonstrating that 
acute or chronic stress decreases BDNF expression in the hippocampus and that diverse 
classes of antidepressants produce the opposite effect and can prevent the actions of stress 
(Berton and Nestler, 2006).  
A dysregulation of the HPA axis, the major neuroendocrine stress system in mammals, has 
also been postulated to play a role in human depression. Hyperactivity of the HPA axis is 
observed in the majority of patients with depression, as manifested by increased expression 
of CRH in the hypothalamus, increased levels of CRH in the cerebrospinal fluid (CSF) and 
reduced feedback inhibition of the axis by CRH and glucocorticoids (Sapolsky, 2000;Barden, 
2004;de Kloet et al., 2005;Deussing and Wurst, 2005;Muller and Holsboer, 2006). 
Although the above mentioned systems are commonly accepted, other neuromodulatory 
systems have also been implicated in depression, e.g. substance P, neuropeptide Y, 
aquaporines, and the immune system, in particular the activation of cytokines (Rosenkranz, 
2007;Kong et al., 2009;Morales-Medina et al., 2010;Blume et al., 2011). Most likely, neither of 
the theories will ever hold true on its own in explaining all underlying mechanisms of 
depression. An interaction of these systems, combining dysregulations of more than one 
neuronal circuit with environmental factors, is probably more likely to explain the etiology 
of depression. Nevertheless, these theories represented initial starting points for the 
generation of possibly valid “depression-models”. Among many of the generated mouse 
mutants based on the mentioned hypothesis, only very few, if any, can be considered valid 
genetic depression models, but rather represent models of predisposition to depression 
(Cryan and Mombereau, 2004). Some of the seminal genetic models will be discussed in 
more detail below.  
3.3.1 Models based on the monoamine hypothesis of depression  
Several knockout mice of candidate genes related to the monoamine hypothesis were 
generated in the past. The main ones included the serotonin-(SERT), noradrenaline 
(NAT)-, and dopamine (DAT) transporters, which represent major targets of 
antidepressants and psychostimulants such as cocaine and 3,4-methylendioxy-N-
methylamphetamine (MDMA/ecstasy). The monoamine transporters (MATs) are 
localized at the presynaptic mebranes of monoaminergic neurons where they modulate 
the fate and restrict the lifetime of the released monoamines (Haenisch and Bonisch, 2011). 
Most classical antidepressants act via MAT inhibition thereby increasing the availability 
of monoamines in the synaptic cleft. Thus one would speculate that MAT knockouts 
would show a similar phenotype to that observed after antidepressant treatment. 
Interestingly, SERT knockout mice show a strong anxiety-like phenotype and are not 
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resistant to depression. Although they display an excess of extracellular 5HT during 
embryonic development, marked depletion of 5HT was shown in several regions of the 
adult mouse brain (Bengel et al., 1998). This favoured the assumption that life-long 
absence of SERT can lead to chronic serotonin depletion resulting in depression-like 
behaviour (Gross et al., 2000;Gross et al., 2002).  
In order to study the endophenotypes of dopaminergic dysregulation Caron and co-workers 
(Giros et al., 1996) developed conventional DAT knockout (DAT-KO) mice. These animals 
show persistent hyperdopaminergia, resulting in a downregulation of pre- and postsynaptic 
dopamine receptors (Gainetdinov et al., 1999;Jones et al., 1999). Concerning the behavioural 
phenotype, DAT-KO mice show very pronounced hyperlocomotion (Giros et al., 
1996;Gainetdinov et al., 1999;Pogorelov et al., 2005), decreased immobility in the FST 
(Spielewoy et al., 2000), increased sucrose preference (Perona et al., 2008), impairments in 
cognitive function (Gainetdinov et al., 1999) and deficits in reversal learning (Morice et al., 
2007). These observations support a certain role of the dopamine transporter in mediating 
an antidepressant-like phenotype. 
In contrast, the phenotype of conventional NAT knockouts fits the profile of 
antidepressant efficacy of drugs that antagonize the noradrenalin transporter (Xu et al., 
2000). These mice behave like antidepressant-treated animals, exhibiting decreased 
immobility in the FST and TST (Xu et al., 2000) as well as increased sucrose consumption 
(Haenisch et al., 2009). In addition, NAT knockout mice show less susceptibility towards 
acute and chronic stress (Haenisch et al., 2009). Thus, NAT knockout animals seem to be a 
good model to obtain more in-depth knowledge on the pathophysiology of depression 
and antidepressant action.  
MAT deficient mice represent interesting tools to study human genetic conditions in which 
these transporters are downregulated, but render them less useful for investigating their 
normal role in the adult brain. It should also be noted that monoamine transporters can 
often compensate for each other if they are completely knocked out (Haenisch and Bonisch, 
2011). For example, noradrenaline can be taken up and stored in striatal dopaminergic 
neurons (Gobert et al., 2004). These compensatory processes represent an additional 
difficulty in understanding the transporter role in the adult brain. In this regard, the 
conventional SERT and DAT knockout mice rendered insights into the brain serotonergic 
and dopaminergic systems, but could not fully address the involvement of these 
monoamines in a depression-like state.  A conditional knockout of SERT and DAT within 
the CNS serotonergic and dopaminergic neurons, respectively, would greatly aid in this 
undertaking. Unfortunately, until now, no tissue-specific conditional knockouts of the SERT 
and DAT have been generated. However, SERT knockdown via siRNA led to a reduction of 
SERT mRNA levels in the dorsal and medial raphe nuclei as well as immobility in the FST, 
which was identical to the response obtained from wildtype mice treated with the 
antidepressant citalopram (Hoyer et al., 2006). Knockdown of the dopamine transporter 
within the ventral tegmental area led to behavioural alterations also found in patients with 
bipolar disorder (Young et al., 2010;Young et al., 2011). These models represent interesting 
and valuable pharmacological tools and stress the importance of developing conditional 
monoamine-transporter knockouts in the future.  
In addition to MATs, conventional monoamine receptor mutant mice also mimic some 
aspects of depression-like behaviour. Fourteen subtypes of 5HT receptors have been 
identified so far (Hoyer and Martin, 1997) many of which have been targeted genetically 
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(Holmes, 2001). However, it is far from clear which receptors are mediating specific aspects 
of emotional behaviour. So far, the 5HT1A receptor (5HT1A-R) has been investigated in 
greater detail. 5HT1A-R knockouts display increased anxiety-related behaviour (Heisler et 
al., 1998;Ramboz et al., 1998;Sibille et al., 2000)  and HPA axis dysregulation (Gross et al., 
2000). Most of the other serotonin receptor knockout mice show no behavioural alterations. 
Although the behavioural effects in 5HT1A-R knockout mice were rather small, they still 
represent a valuable pharmacological model to study pharmacodynamical, biochemical and 
behavioural characteristics of serotonergic antidepressants (Urani et al., 2005). Similarly, 
there are hardly any pharmacological tools available that are selective enough to 
discriminate between the different subtypes of 2 adrenergic receptors. Thus, mice carrying 
deletions for these receptors could help to better understand receptor function and improve 
drug specificity. Mutant 2A adrenergic receptor mice show an increase in anxiety-like 
behaviour (Lahdesmaki et al., 2002), increased immobility in the FST and have a disrupted 
circadian rhythm (Schramm et al., 2001), a symptom often observed in human depression.  
Although monoamine receptor KOs represent valuable pharmacological tools, they are 
limited in their value as an animal model of depression. This is mostly due to the fact that 
deletion of a signal receptor is probably not sufficient to induce reliable depression-like 
phenotypes. In addition, compensatory mechanisms in early embryogenesis can lead to 
misinterpretations of receptor function pointing out once more the importance of 
conditional KOs.  
3.3.2 Models based on the neurotrophic factor-related hypothesis of depression 
The neurotrophin hypothesis of depression has also been addressed in the mouse by 
targeting neurotrophic factors such as BDNF and the respective TRKB receptors. However, 
conventional BDNF and TRKB receptor KOs are not viable (Conover et al., 1995). Thus, most 
of the earlier studies were conducted with heterozygous knockout mice. These were 
behaviourally indistinguishable from control littermates, consequently not representing a 
genetic model of depression (MacQueen et al., 2001). In contrast, forebrain-specific BDNF 
deletion leads to hyperactivity, obesity and increased anxiety-like behaviour (Rios et al., 
2001). In addition, inducible knockout of BDNF from the hippocampus and other forebrain 
regions prevented the antidepressant effects of certain reuptake inhibitors (Monteggia et al., 
2004). These animal models were of great value in linking the role of BDNF in the adult 
brain with antidepressant-like activity of certain drugs. However, complications arise from 
the fact that BDNF seems to exert quite opposite effects in different neural circuits. Although 
it shows antidepressant-like effects at the level of the hippocampus, BDNF infusion into the 
ventral tegmental area induces a prodepression-like effect (Eisch et al., 2003;Berton and 
Nestler, 2006). Conversely, conditional forebrain deletion of the BDNF receptor TRKB 
induced only a few behavioural changes, many of which are inconsistent (Zorner et al., 
2003). Nevertheless, the conditional BDNF knockouts significantly contributed to the 
dissection of the role of BDNF in depression-related behaviours and responses to 
antidepressant drugs.  
3.3.3 Models based on alterations of the HPA axis  
3.3.3.1 The CRH/CRHR1 System 
The generation and analysis of numerous constitutive mouse mutants affecting different 
parts of the HPA axis is another example where genetically modified mice have 
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demonstrated their enormous potential. The genetic dissection of the organism’s major 
stress-integrating system in the mouse has confirmed a major role of corticosteroid receptors 
and of the CRH system in the pathogenesis of affective disorders including depression 
(Deussing and Wurst, 2005). Therefore it seemed obvious to target the major player of the 
system, CRH. However, homozygous CRH knockout mice are viable and show no 
behavioural abnormalities compared to control littermates (Muglia et al., 1995). Basal 
pituitary ACTH secretion is compensated by an increased expression of the co-secretagogue 
neuropeptide vasopressin (AVP), thus CRH deficiency impairs but does not fully block 
pituitary-adrenal responses to diverse stressors (Venihaki and Majzoub, 1999). In contrast, 
conventional CRH receptor 1 knockouts display a severe impairment of stress-induced HPA 
axis activation and marked glucocorticoid deficiency (Muller and Holsboer, 2006). In 
addition, they demonstrate increased locomotor activity and decreased anxiety-like 
behaviour, both under basal conditions and after ethanol withdrawal (Timpl et al., 
1998;Sillaber et al., 2002). As a result, conventional CRHR1 deletion was shown to affect 
behaviour as well as neuroendocrine regulation, which obstructs the analyses of the role of 
CRH as a neuromodulator independent of HPA axis activation. By generating forebrain-
specific CRHR1 knockouts, this problem was overcome (Muller et al., 2003). These animals 
demonstrated a marked decrease in anxiety-related behaviour, which was not influenced by 
central nervous system effects of circulating stress hormones. In addition, forebrain CRHR1 
deficiency has been shown to attenuate chronic stress-induced cognitive deficits and 
dendritic remodelling (Wang et al., 2011). However, it remains a matter of debate which 
brain structures and circuits are mediating anxiety-like behaviour in mice. So far, most of 
the results provide evidence that amygdalar CRHR1 is responsible for the observed 
phenotypes (Liebsch et al., 1995;Sztainberg et al., 2010). Thus it would be of great 
importance to further dissect the origin of these effects by generating mice with deletions of 
CRHR1 in certain neuronal subpopulations and/or specific brain regions.  
Taking into account that depression is often accompanied with excessive glucocorticoids 
and elevated CRH levels in the cerebrospinal fluid, the generation of mice overexpressing 
CRH was of utter importance. Different lines of CRH-overexpressing mice consistently 
display an increase in anxiety-related behaviour (Stenzel-Poore et al., 1996;Kolber et al., 
2010). However, in all cases unrestricted CRH overexpression resulted in elevated 
corticosterone levels accompanied by symptoms of Cushing-like syndrome, complicating 
the interpretation of stress-related behavioural results. This problem was circumvented by 
designing mutants overexpressing CRH under the CNS-specific Nestin and the forebrain-
specific Camk2a promotors (Lu et al., 2008). In both lines, the basal HPA axis activity 
remained unaltered. CRH overexpression in the whole CNS, but not when expressed in 
specific forebrain regions, resulted in stress-induced hypersecretion of corticosterone and 
decreased immobility in the FST and TST (Lu et al., 2008). These changes were probably due 
to acute effects of overexpressed CRH as they were normalized by CRH-R1 antagonist 
treatment. However, forebrain-specific CRH overexpression during postnatal development 
was shown to cause long-lasting anxiogenic and despair-like phenotypes (Kolber et al., 
2010). This supports the hypothesis that CRH in limbic regions such as the amygdala, 
hippocampus and prefrontal cortex can induce anxiety-like changes. This further coincides 
with results obtained from conditional forebrain-specific CRHR1 knockout animals, which 
demonstrate decreased anxiety-like behaviour. However, the problems concerning ectopic 
expression cannot be neglected and thus it remains unclear whether CRH overexpressing 
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mouse mutants show sufficient, if any, construct validity.  The best way to address this issue 
would be to generate a CRH overexpressing mouse under the control of its endogenous 
promoter, thereby restricting the overexpression to its actual expression sites. 
3.3.3.2 Glucocorticoids and glucocorticoid receptors 
Excessive stimulation of the HPA axis, implicated in depression, is mostly reflected by 
excessive glucocorticoids. Conventional glucocorticoid receptor knockouts have thus been 
developed in order to address the function of the GR in depression. Initially, a GR-
antisense transgenic mouse was developed (Pepin et al., 1992), which demonstrated 
behavioural and neuroendocrine signs and symptoms common among depressed 
patients. These included reduced negative feedback sensitivity to dexamethasone (Stec et 
al., 1994) and enhanced stress hormone response (Pepin et al., 1992). Most importantly, 
this model showed good predictive validity evident in an antidepressant response which 
induced numerous changes including increased GR mRNA, reduced HPA axis activity 
(Montkowski et al., 1995) and enhanced hippocampal LTP (Steckler et al., 2001). A few 
years later, conventional GR knockouts were developed (Cole et al., 1995). These showed 
a similar phenotype to that observed in GR-antisense transgenic mice. In addition, they 
exhibited increased helplessness after stress exposure and reduced hippocampal BDNF 
content (Ridder et al., 2005). Forebrain-specific GR deletion produces non-suppression of 
corticosterone following dexamethasone administration, altered circadian HPA axis 
activity, and increased hypothalamic vasopressin expression, which are all hallmarks of 
depression. Interestingly, they also exhibited a robust despair-like phenotype, which was 
reverted by antidepressant treatment (Boyle et al., 2005). Taking into account the 
observations from the conventional GR knockouts, it does not seem surprising that GR 
antagonists are being considered and currently tested as possible non-monoamine-based 
antidepressants.  
Conditional, forebrain-restricted overexpressing GR mutants were also developed in 
order to address the function of the receptor in the pathophysiology of depression. 
However, increased GR expression specifically in the forebrain is unlikely to occur under 
normal circumstances (Muller and Holsboer, 2006). Nevertheless, some important insights 
into how the GR modulates emotional responsiveness have been obtained (Wei et al., 
2004). Increased anxiety-related behaviour was observed in conditional GR 
overexpressing mice, which was reverted by desipramine treatment. However, the HPA 
axis remained unchanged, rendering this line a model of “increased emotional lability”. In 
contrast, when GR overexpression was achieved by means of inserting two additional 
copies of the gene using a yeast artificial chromosome, the animals demonstrated a stress-
resistant HPA system and showed reduced helplessness after stress exposure (Reichardt 
et al., 2000). However, it should be noted that in this case the GR overexpression was not 
restricted to the central nervous system. In this regard, both transgenic lines provided 
some insights concerning stress responsiveness, but are not very suitable as a model for 
depression. 
It becomes quite clear that no single model fulfils all the criteria necessary to be coined 
“depression-model”. Future technologies, such as constitutive and conditional RNAi 
transgenesis, zinc-finger and optogenetic approaches will have a great impact on the 
development of more suitable models for depression and other psychiatric disorders.  
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4. Next generation of genetic models – new techniques and strategies 
4.1 Models based on Genome-Wide Association Studies (GWAS) 
In a genome-wide association study (GWAS) a large number of genetic polymorphisms 
across the whole genome is examined to identify genetic associations with an observable 
trait or disease. The power of a GWAS is restricted by the sample size and the technical 
properties of the genotyping platform used with regard to the coverage of genomic 
locations. GWASs can be used to detect case-control- or family-based associations 
(Craddock et al., 2008). The great advantage of this method compared to classical candidate 
gene studies is that it allows genetic investigation of a disease in a non-hypothesis-driven 
manner. Using this unbiased approach increases the possibility to find new and even 
unexpected genes associated with a certain disease. A key factor for this kind of study is a 
preferably large sample size in order to detect even small effect sizes. There is evidence that 
for psychiatric disorders most of the heritable risk is due to interactions of combinations of 
genetic risk variants each with a relatively small effect on the general outcome (Cichon et al., 
2009). An obvious challenge concerning the genetic investigation of psychiatric disorders in 
comparison to non-psychiatric diseases is that the phenotype and the clinical picture of 
mood disorders are more difficult to define. Therefore, the patient samples used for a 
GWAS are often rather heterogeneous with regard to sex, age, symptoms, environmental 
factors and other issues. To increase the statistical power of GWAS studies a so-called meta-
analysis can be performed by pooling all GWAS data available for a certain disease and 
subsequent statistical evaluation in order to increase the sample size. Associations for 
several candidate genes have been identified in a meta-analysis of genetic studies on major 
depression, including apolipoprotein E (APOE), dopamine receptor D4 (DRD4), guanine 
nucleotide-binding protein (GNB3), methylenetetrahydrofolate reductase (MTHFR), 
dopamine transporter (SLC6A3) and serotonin transporter (SLC6A4) (Lopez-Leon et al., 
2008). Additionally, several associations with immune-related genes have been reported, for 
instance P2RX7 which is a purinergic ATP-gated calcium channel that modulates 
macrophage-induced inflammatory responses and is also expressed in neurons and glia cells 
in the brain. A non-synonymous coding SNP in the P2RX7 gene (rs2230912) leading to an 
amino acid substitution (Gln460Arg) has been found to be associated with major depression 
and bipolar disorder in several independent studies (Barden et al., 2006;Lucae et al., 
2006;McQuillin et al., 2009;Hejjas et al., 2009;Soronen et al., 2011). These data highlight 
P2RX7 as a new interesting candidate gene for mood disorders even though these findings 
need further investigation. The proper way to validate the biological significance of such 
implicated risk variations is the generation of an appropriate in vivo model. Using knock-in 
mouse models, human association data can be validated and pharmacological compounds 
can be tested in vivo. In a study of Chen et al (Chen et al., 2006) a common single-nucleotide 
polymorphism (SNP) in the brain-derived neurotrophic factor (BDNF) gene, leading to a 
substitution of methionine for valine at codon 66 (Val66Met) was investigated in a mouse 
model carrying the BDNF variant. This SNP was shown to be associated with alterations in 
brain anatomy and memory, but its relevance for psychiatric disorders has been unclear. In 
response to stress these mutant mice exhibited increased anxiety-related behaviour 
suggesting that this genetic predisposition combined with an environmental challenge may 
increase the risk to develop anxiety and depressive disorders (Chen et al., 2006). 
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4.2 Generating models using optogenetics 
The use of traditional electrophysiological, pharmacological and genetic methods goes along 
with considerable deficits, which make them partly unsuitable to study neural circuits with 
fine spatial and temporal resolution in vivo (Carter and de, 2011). To overcome these 
limitations, a new technology termed optogenetics (Deisseroth et al., 2006) has been 
developed to precisely stimulate, inhibit or alter the activity of specific cells and their 
processes with high temporal accuracy and rapid reversibility. The special feature of this 
approach are effectors which can be activated by light and are genetically encoded allowing 
direct control of specific cell populations in vitro and in vivo. The most commonly used 
optogenetic effectors are genetically engineered variants of natural opsins, light-sensitive 
ion channels that can be stimulated in response to specific wavelengths of light leading 
either to membrane depolarisation, hyperpolarisation or change in intracellular signalling 
(Carter and de, 2011). The first class includes channelrhodopsin-2 (ChR2), isolated from the 
green algae Chlamydomonas reinhardtii which is sensitive to blue light and has already 
successfully been used in transgenic mice (Arenkiel et al., 2007;Tsai et al., 2009;Huber et al., 
2008). Photons are absorbed by the all-trans-retinal cofactor of ChR2 that is endogenously 
expressed at sufficient levels in the central nervous system of vertebrates (Li et al., 2005;Bi et 
al., 2006;Ishizuka et al., 2006;Zhang et al., 2006). ChR2 can be activated and closed very 
rapidly upon light on- and offset, respectively, allowing stimulation of neurons within 
milliseconds (Boyden et al., 2005;Li et al., 2005). The inhibitory counterpart of ChR2, the 
chloride pump halorhodopsin (NpHR), was isolated from the bacteria Natronomonas 
pharaoni and possesses an activation spectrum in the yellow range, complementary to that of 
channelrhodopsin. Similarly to ChR2, NpHR uses all-trans retinal as chromophore and can 
therefore be applied in vertebrate organisms without exogenous cofactors. By expressing 
both proteins in the same cell, one can either activate or silence it by illumination with 
different wavelengths (Fiala et al., 2010). A third strategy is to design artificial rhodopsin-
GPCR chimeras that combine the light responsive elements of rhodopsin with the 
biochemical signalling functionality of specific GPCRs termed Opto-XRs (Kramer et al., 
2009;Airan et al., 2009). Recently, this method was used to develop an Opto-XR that controls 
serotonin signalling via the 5-HT(1A) receptor (Oh et al., 2010). 
Several studies have used optogenetic techniques to investigate the neural circuitries and 
molecular mechanisms underlying mammalian behaviour and the etiology of neurological 
disorders (Carter and de, 2011). For instance, recent studies used optogenetics to dissect the 
neural circuitry within basal ganglia underlying Parkinson´s disease (Gradinaru et al., 
2009;Kravitz et al., 2010). It was also shown that optogenetic stimulation of the locus 
coeruleus (LC) leads to an immediate shift from sleep to wakefulness whereas optogenetic 
inhibiton causes a decrease in wakefulness (Carter and de, 2011). However, sustained 
stimulation of the LC produces a behavioural state resembling cataplexy, a transient loss of 
muscle tone which is a hallmark of narcolepsy. These results suggest that overstimulation 
can cause behavioural arrests similar to those seen in neuropsychiatric disorders. In 
addition, using optogenetics, selective phasic photostimulation of dopaminergic neurons in 
the ventral tegmental area (VTA) was able to trigger behavioural conditioning whereas tonic 
activity was not (Tsai et al., 2009). Stimulation of dopaminergic neurons in the VTA led to 
secretion of glutamate into the nucleus accumbens in addition to dopamine, suggesting that 
mesolimbic reward signalling may involve glutamatergic transmission (Tecuapetla et al., 
2010;Stuber et al., 2010). Many other studies using optogenetic probes have been performed, 
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including associative fear memory (Ciocchi et al., 2010;Johansen et al., 2010;Haubensak et 
al., 2010), epilepsy (Tonnesen et al., 2009) and others. Thus, optogenetics represents an 
uprising and promising technique in molecular brain research, which will certainly aid in 
the development and analysis of new mouse models of depression.  
4.3 Mouse engineering by means of zinc finger nucleases 
Another new promising technique called genome editing enables efficient and precise 
genetic modification by induction of a double-strand break in a specific target sequence in 
the genome using zinc finger nucleases (ZFN), followed by the generation of genetic 
modifications during subsequent DNA repair. These zinc finger nucleases are sequence-
specific endonucleases that can be modified to cleave a desired DNA target. This method 
was initially applied to Drosophila melanogaster (Bibikova et al., 2002) and has already been 
used to disrupt endogenous loci in rats (Geurts and Moreno, 2010), by using this technique, 
basically any eukaryote can be genetically modified.  
Genetic disruption using this technology is achieved by taking advantage of errors 
introduced during DNA repair to destroy the function of a gene or genomic region in a 
single step without selection for the desired event (Urnov et al., 2010). This process is called 
non-homologous end-joining, a template-independent and therefore imperfect repair 
mechanism resulting in deletions or insertions. For gene disruption in rats, engineered zinc 
finger nucleases with extended recognition sites were used to produce knockout animals for 
two different endogenous genes, and transmission of the disrupted alleles occurred at a 
frequency of 10–100% (Geurts and Moreno, 2010). The great advantage of this ZFN-driven 
knockout approach is that only one generation is needed, and compares favourably with 
others strategies such as classical gene targeting in mouse embryonic stem cells considering 
duration and screening effort.  
A second, more complex approach using a ZFN-induced double-strand break which is 
recombinogenic in higher eukaryotes is called homology-based genome editing. This 
technique requires the simultaneous provision of an appropriately designed, homology-
containing donor DNA molecule along with the locus-specific ZFNs. This enables the study 
of gene function and modelling of disease-causing mutations through the creation of a point 
mutation that is characteristic of a known disease-predisposing allele or that disables a motif 
that is thought to be crucial for function (Urnov et al., 2010). This method was applied to 
three different genes in D. melanogaster, and in up to 90% the offspring of treated animals 
carried the donor-specific alleles of the target gene (Beumer et al., 2006). 
Meyer and colleagues have recently explored whether gene targeting can be directly 
performed in murine zygotes by the use of zinc-finger nucleases. They reported that gene 
targeting could be successfully achieved in murine one-cell embryos upon the coinjection of 
targeting vectors with zinc-finger nucleases, without preselection (Meyer et al., 2010).  
Using the ZFN technology will enable to identify and validate genes involved in complex 
diseases such as depression. Especially for the validation of candidate genes for disease 
susceptibility identified in linkage and association studies this method could provide a 
powerful tool in the future (Geurts and Moreno, 2010). 
Furthermore, other types of nucleases based on engineered transcription activator-like 
effectors (TALEs) are currently under development (Christian et al., 2010). TAL effector 
nucleases have the advantage that they are very simple to engineer and have already been 
used to target endogenous loci in human cells (Miller et al., 2011). Up to now, no transgenic 
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organisms based on TALE nuclease technology have been reported yet, but this certainly is 
just a matter of time. 
5. Mouse models based on environmental challenges 
Besides genetic risk factors, many studies have implicated environmental alterations 
including stressful life events with the development of affective disorders (Pezawas et al., 
2005;Ising and Holsboer, 2006). Exposure to stress or to traumatic life experiences has a 
strong impact on the manifestation of depression, suggesting an impairment of proper 
stress-coping strategies in depressed patients (Kessler, 1997;de Kloet et al., 2005). Therefore, 
depression is also regarded as a stress-related disorder, and, accordingly, many of the 
animal models of depression are based on the exposure to various types of acute or chronic 
stressors. However, up to now little consensus exists on the definition of stress. Many 
studies interpret the presence of a stress response, evident in a sudden increase of 
corticosterone, as an indicator of stress exposure. However, appetitive and rewarding 
situations such as sexual behaviour and winning a social interaction elicit HPA axis 
responses that are similar in magnitude as highly aversive situations like social defeat 
(Koolhaas et al., 2011). This points out that the physiological response per se does not 
necessarily indicate a state of stress. In other words, when is a stimulus a stressor and what 
makes a response a stress response? Koolhaas and colleagues agreed on the view that stress 
should be considered as a cognitive perception of uncontrollability and/or unpredictability 
that is expressed in a physiological and behavioural response. Hence, an unpredictable 
situation should be characterized by the absence of an anticipatory response, whereas 
uncontrollability can be defined as a reduced recovery of the neuroendocrine reaction 
(Koolhaas et al., 2011). In that regard the most prominent models will be explained below.  
5.1 Chronic stress models 
The chronic character of stressors is generally considered an important factor in the 
development of various forms of stress-related pathologies. Several chronic stress 
procedures have been employed in the past, trying to achieve a measure of construct and 
face validity. Chronic mild or chronic unpredictable stress involves exposing rodents to a 
series of repeated physical stressors, including foot shock, restraint, low temperatures, loud 
music etc, over a period of weeks or longer (Willner, 2005;Nestler and Hyman, 2010). 
Towards the end of the stress procedure the animals develop signs of anhedonia, which can 
be reverted by chronic, but not acute, administration of antidepressants. Although this 
model shows aspects of construct and face validity, it is not easily reproduced across 
laboratories. This is probably caused by repeated exposure to a certain stimulus, which 
eventually renders it predictable. Thus, stimuli which have been perceived as stressors at 
the beginning cease to be perceived as such after a while. This holds especially true for 
repeated restraint (immobilization) stress in view of the strong decline of the physiological 
response upon its repetition (Grissom et al., 2008). In this regard, some commonly used 
animal models of chronic stress may represent models of adaptation rather than models of 
stress-related pathology (Koolhaas et al., 2011). A means of circumventing this problem is to 
use stressors with a certain degree of ecological validity. These stressors should be 
unpredictable, uncontrollable and challenge the natural defence mechanisms of the animal. 
So far only a few models seem to meet these criteria including chronic social defeat stress. 
Here, an animal is repeatedly exposed to an aggressive dominant animal, leading to social 
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subordination, after which the mice show a range of depression-like symptoms, including 
anhedonia, social withdrawal and cognitive impairments (Berton et al., 2006;Wang et al., 
2011). Most of these are reversible by chronic, but not acute, antidepressant treatment 
(Berton et al., 2006). In addition, chronic social defeat was shown to induce a metabolic 
syndrome in mice characterized by weight gain, insulin and leptin resistance (Chuang et al., 
2010), consistent with homeostatic abnormalities observed in depressed patients. In 
addition, experience of social defeat leads to changes in the state of the serotonergic and 
noradrenergic systems of various parts of the brain (Berton et al., 1998). A further advantage 
of chronic social defeat is the potential to segregate defeated subjects into susceptible and 
unsusceptible populations on the basis of considerable individual variance to social defeat 
behavioural outcomes (Krishnan et al., 2007). Thus, the social defeat procedure exhibits 
features of construct, face and predictive validity, although the intensity of the stress used is 
more severe than that seen in humans. The main drawback of chronic stress paradigms is 
that the evoked phenotypes often “resemble social anxiety” and not depression. It is difficult 
to identify the required stress duration which induces depression-like symptoms rather than 
sole anxiety responses. Kudryavtseva and colleagues propose that longer sessions of social 
stress (at least 20 days) are required to induce depression-like phenotypes, whereas Nestler 
and colleagues claim to observe such behavioural alterations already after 10 days (Berton et 
al., 2006). Additional studies will help to further elaborate on this aspect and possibly pave 
the road for improved strategies in modelling depression.  
5.2 Early life stress models 
Similar validity compared to the chronic social defeat model was achieved for early life 
stress, including prenatal stress, early postnatal handling, and most of all maternal 
separation (Francis et al., 1996;Ladd et al., 2000;Caldji et al., 2000;Meaney, 2001). Traumatic 
life events in childhood have been shown to result in an increased sensitivity to the effects of 
stress later in life and alter the individual’s vulnerability to stress-related psychiatric 
disorders such as depression (Graham et al., 1999;Heim and Nemeroff, 2001). Early life 
stress in mice produces neuroendocrine and behavioural changes that persist into 
adulthood, some of which can be reverted by antidepressants (Meaney, 2001). The most 
widely used model is the maternal separation paradigm of early life deprivation, in which 
pups are separated from the dam for 1-24 h per day during the first two postnatal weeks. 
This results in increased anxiety-like and despair-based behaviour as well as increased HPA 
axis response, all of which can be observed in adulthood (de Kloet et al., 2005). It is 
important to mention that shorter periods of separation tend to produce opposite effects. 
Thus early life challenges may conversely induce changes that prepare an individual for life 
in a more hostile environment and therefore be predominantly beneficial. Hence, it has be 
proposed that adult diseases such as depression might not be promoted by early life 
adversity per se, but by a mismatch of the programmed and the later actual environment in 
combination with a more vulnerable or resilient genetic predisposition (Schmidt, 2011). 
Although the exact physiological nature of the effects of postnatal maternal separation is not 
fully understood, the paradigm demonstrated its value for studying the neurobiological 
basis of the impact of early life stress on emotional behaviour (Cryan and Holmes, 2005).  
More recently, a new early life stress model based on similar principles has been developed. 
The main difference is that the new model omits the separation from the mother and 
thereby avoids metabolic disturbances, exhaustion, or hypothermia of the pups. This is 
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evoked by means of fragmented maternal care, generated by reducing the amount of nesting 
and bedding material available to the dam (Rice et al., 2008).  
6. Gene-environment interactions 
Although chronic stress has been implicated in the onset of psychiatric disorders, it has to be 
kept in mind that not all individuals exposed to severe stress will progress to disease. In that 
sense, it is also quite unlikely that a single genetic variant is responsible for a specific 
disorder. Therefore, it is of great necessity to understand the cause of individual differences 
and the consequences of variation in vulnerability, with regard to disease progression. It is 
clear that major efforts should be directed towards the combination of genetic modifications 
and environmental challenges in the same subject. Such stimulation of gene-environment 
interactions is more likely to reflect the pathophysiological mechanisms of depression. Many 
studies have already applied this concept by subjecting transgenic lines to chronic social 
stress procedures (Berton et al., 2006;Wagner et al., 2010;Wang et al., 2011). These studies 
provide further evidence that disease-associated genetic alterations do not have to be 
pathological/beneficial under normal conditions, but in combination with chronic stress can 
either cause vulnerability or resilience towards the development of depression-like 
phenotypes.  
7. Classical antidepressants – limitations and future prospects 
The majority of antidepressant drug discovery efforts during the past decades have focused 
on finding more selective serotonin- or noradrenaline-based agonists or antagonists having 
modes of action similar to already available drugs, only with the ability to act more quickly 
and safely. However, until now this approach has not lead to improved treatment. There are 
some novel drugs known as atypical antidepressants which have ascribed monoamine-
based mechanisms, but there is only weak evidence that their implied mechanisms actually 
account for their clinical efficacy. In parallel, non-monoamine systems that might contribute 
to the pathophysiology of depression have been analyzed in the past, revealing potential 
biomarkers for depression, such as CRH, P2RX7, BDNF, etc. (see above). However, none of 
these discoveries has been translated into a new bona fide treatment for depression so far. 
Ironically, the search for non-monoamine-based antidepressants has often relied on the 
actions of monoamine-based drugs. This highlights the necessity to develop improved 
animal models of depression. Applying the techniques and approaches mentioned above 
should aid in this undertaking and hopefully translate into the development of new 
treatment modalities apart from classical antidepressants.  
8. Conclusion 
The major problem in the establishment of a suitable animal model of depression is that the 
development of such a model requires a better understanding of the etiology of the disorders. 
The current state of clinical knowledge lacks objective diagnostic tests and validated 
biomarkers of such a highly heterogeneous illness. However, such models are of great 
necessity for understanding disease pathophysiology and for hastening the development of 
treatments based on new molecular targets. We have given a general overview of the current 
mouse models of depression and outlined some of the difficulties in the generation and 
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validation of such models. In addition, new strategies and technologies have been discussed, 
which will greatly contribute to our understanding of disease pathology. Nevertheless, it is 
very unlikely that mice will ever recapitulate all of the salient features of a human mental 
illness. Above all, models are meant to serve as investigative tools. In that regard, researchers 
should critically judge construct, face and predictive validity and not simply assume that 
behavioural alterations in one or more tests are sufficient to render a model of depression. In 
addition, differences between males and females are often not addressed in preclinical 
research. Extensive literature reports that mood disorders are more frequent in women than in 
men, but the great majority of basic research has focussed on male rodents as animal models 
(Palanza, 2001). This emphasizes the need for reliable depression models in females. In 
addition other endophenotypes of depression, such as alterations in sleep, should also be 
addressed more consistently in mice. To accomplish the goal of creating more appropriate 
animal models of depression, it will be necessary to implement and combine all recent 
advances in genetics, pharmacology and electrical stimulation with environmental challenges 
(Fig. 1). This will hopefully initiate the development of new treatment modalities which are 
based on knowledge and not serendipity.  
 
 
Fig. 1. Towards an ideal mouse model of depression. 
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In order to generate more suitable depression models with strong construct validity, major 
efforts should be directed towards the combination of genetic modification and 
environmental challenges in the same subject. This would simulate gene-environment 
interactions that more plausibly reflect the pathophysiological mechanisms of depression. 
Such models should show sufficient face validity, as assessed by behavioural and/or 
physiological parameters and respond to classical and/or novel drugs (predictive validity).  
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